UBS Maintains Buy on Insmed, Raises Price Target to $84
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Trung Huynh maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $78 to $84.
August 09, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Trung Huynh maintains a Buy rating on Insmed and raises the price target from $78 to $84.
The Buy rating and increased price target from a reputable analyst at UBS is likely to positively influence investor sentiment and drive short-term price appreciation for Insmed.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100